Wells Fargo initiated coverage on Kiniksa Pharmaceuticals with a new price target
$KNSA
Biotechnology: Pharmaceutical Preparations
Health Care
Wells Fargo initiated coverage of Kiniksa Pharmaceuticals with a rating of Overweight and set a new price target of $34.00